跳至主要内容
临床试验/EUCTR2011-002222-46-NL
EUCTR2011-002222-46-NL进行中(未招募)1 期

In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR-II studyA randomized controlled pilot study - VECTOR II study

Radboud University Nijmegen Medical Centre0 个研究点目标入组 20 人开始时间: 2013年3月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Age = 18 and = 35 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Use of any medication
  • Congenital or acquired C1 inhibitory deficiency
  • Immune deficiency
  • Chronic inflammatory diseases
  • History of allergic reaction to blood products
  • History, signs or symptoms of cardiovascular diseases
  • (Family) history of cerebrovasculair diseases under the age of 65 years
  • Previous vagal collaps
  • Hypertension (defined as RR systolic > 160 or RR diastolic > 90)
  • Hypotension (defined as RR systolic < 100 or RR diastolic < 50)
  • Renal impairment (defined as plasma creatinin > 120 µmol/l)
  • Liver enzyme abnormalities

研究者

发起方
Radboud University Nijmegen Medical Centre

相似试验